234 related articles for article (PubMed ID: 32236959)
1. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
Vreman RA; Naci H; Goettsch WG; Mantel-Teeuwisse AK; Schneeweiss SG; Leufkens HGM; Kesselheim AS
Clin Pharmacol Ther; 2020 Aug; 108(2):350-357. PubMed ID: 32236959
[TBL] [Abstract][Full Text] [Related]
2. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
[TBL] [Abstract][Full Text] [Related]
3. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
4. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
[TBL] [Abstract][Full Text] [Related]
5. New trends and challenges in the European regulation of innovative medicines.
Enzmann H
Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
7. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.
Yang WW; Juan YC; Wu GH; Pwu RF
Drug Saf; 2024 Apr; 47(4):289-299. PubMed ID: 38113017
[TBL] [Abstract][Full Text] [Related]
8. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
9. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
11. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.
Salas-Vega S; Iliopoulos O; Mossialos E
JAMA Oncol; 2017 Mar; 3(3):382-390. PubMed ID: 28033447
[TBL] [Abstract][Full Text] [Related]
13. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
14. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
15. HTA Barriers for Conditional Approval Drugs.
Mills M
Pharmacoeconomics; 2023 May; 41(5):529-545. PubMed ID: 36821044
[TBL] [Abstract][Full Text] [Related]
16. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
[TBL] [Abstract][Full Text] [Related]
17. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
18. Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.
Vreman RA; Bouvy JC; Bloem LT; Hövels AM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG
Clin Pharmacol Ther; 2019 Mar; 105(3):684-691. PubMed ID: 30300938
[TBL] [Abstract][Full Text] [Related]
19. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
20. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]